- Home
- CB vs VRTX Comparison
CB vs VRTX Comparison
Compare CB & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CB
- VRTX
- Stock Information
- Founded
- CB 1985
- VRTX 1989
- Country
- CB Switzerland
- VRTX United States
- Employees
- CB N/A
- VRTX N/A
- Industry
- CB Property-Casualty Insurers
- VRTX EDP Services
- Sector
- CB Finance
- VRTX Technology
- Exchange
- CB Nasdaq
- VRTX Nasdaq
- Market Cap
- CB 106.9B
- VRTX 96.6B
- IPO Year
- CB 1993
- VRTX 1991
- Fundamental
- Price
- CB $282.89
- VRTX $417.15
- Analyst Decision
- CB Buy
- VRTX Buy
- Analyst Count
- CB 17
- VRTX 26
- Target Price
- CB $308.76
- VRTX $489.48
- AVG Volume (30 Days)
- CB 2.1M
- VRTX 1.3M
- Earning Date
- CB 10-21-2025
- VRTX 11-03-2025
- Dividend Yield
- CB 1.37%
- VRTX N/A
- EPS Growth
- CB N/A
- VRTX N/A
- EPS
- CB 23.94
- VRTX 14.22
- Revenue
- CB $58,842,000,000.00
- VRTX $11,723,300,000.00
- Revenue This Year
- CB N/A
- VRTX $10.95
- Revenue Next Year
- CB $5.16
- VRTX $9.55
- P/E Ratio
- CB $11.83
- VRTX $29.27
- Revenue Growth
- CB 7.43
- VRTX 10.33
- 52 Week Low
- CB $252.16
- VRTX $362.50
- 52 Week High
- CB $306.91
- VRTX $519.88
- Technical
- Relative Strength Index (RSI)
- CB 55.63
- VRTX 52.06
- Support Level
- CB $273.35
- VRTX $403.16
- Resistance Level
- CB $286.57
- VRTX $430.71
- Average True Range (ATR)
- CB 4.26
- VRTX 10.54
- MACD
- CB 0.71
- VRTX -0.98
- Stochastic Oscillator
- CB 81.76
- VRTX 47.26
About CB Chubb Limited
ACE acquired Chubb in the first quarter of 2016 and assumed the Chubb name. The combination made the new Chubb one of the largest domestic property and casualty insurers, with operations in 54 countries spanning commercial and personal P&C insurance, reinsurance, and life insurance.
About VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.